Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study
The consumption and cost of antidiabetic drugs increased with the diabetes prevalence. GLP-1 analogs and SGLT2 inhibitors accounted for the main growth, reflecting their growing clinical adoption and evidence of efficacy, while sales of sulfonylureas and DPP4 inhibitors remained substantial despite concerns regarding their benefit-risk profiles. In 2022, expenditures for GLP-1 analogs surpassed insulin. These findings have implications for healthcare policy and resource allocation planning.
Authors
- Dominik Menges (ORCID: https://orcid.org/0000-0001-5970-1846)
- David De Bandt (ORCID: https://orcid.org/0000-0003-3031-5604)
- Claire Carette (ORCID: https://orcid.org/0000-0002-8175-0369)
- Claire Lange (ORCID: https://orcid.org/0000-0002-2023-1469)
- Johanna Mezence
Institutions
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- University of Zurich (CH)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Centre Hospitalier de Saint-Quentin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Hôpital Européen (FR)
Publication Details
- Journal
- Clinical Therapeutics
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1016/j.clinthera.2025.02.005
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59